Combining spinal neuromodulation and activity based neurorehabilitation therapy improves sensorimotor function in cerebral palsy

Frontiers in Rehabilitation Sciences

Rehabilitation Sciences

Yousef Shirkhani¹  V. Reggie Edgerton²  Parag Gad³  Kristin Girshin⁴  Rahul Sachdeva⁵ 

[1] GirshinPT, Rancho Cucamunga, CA, United States;Rancho Research Institute, Downey, CA, United States;USC Neurorestoration Center, University of Southern California, Los Angeles, CA, United States;Institut Guttmann, Hospital de Neurorehabilitació, Institut Universitari Adscrit a la Universitat Autònoma de Barcelona, Barcelona, Spain;SpineX Inc., Los Angeles, CA, United States;SpineX Inc., Los Angeles, CA, United States;GirshinPT, Rancho Cucamunga, CA, United States;SpineX Inc., Los Angeles, CA, United States;International Collaboration on Repair Discoveries (ICORD), Department of Medicine, University of British Columbia, Vancouver, BC, Canada;

关键词: spinal cord neuromodulation;    noninvasive stimulation;    cerebral palsy;    sensorimotor function;    spasticity;   

DOI  :  10.3389/fresc.2023.1216281

 received in 2023-05-03, accepted in 2023-07-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

Motor dysfunction in individuals with cerebral palsy (CP) such as the inability to initiate voluntary movements, walking with compensatory movement patterns, and debilitating spasticity is due to the aberrant neural connectivity between the brain and spinal cord. We tested the efficacy of noninvasive spinal cord neuromodulation (SCiP™, SpineX Inc.) with activity-based neurorehabilitation therapy (ABNT) in improving the sensorimotor function in six children with CP. Children received 8 weeks of either SCiP™ or sham therapy with ABNT (n = 3 per group). At the end of 8 weeks, all participants received 8 weeks of SCiP™ therapy with ABNT. Follow up assessments were done at week 26 (10 weeks after the last therapy session). Sensorimotor function was measured by the Gross Motor Function Measure 88 (GMFM88) test. We observed minimal change in sham group (mean 6% improvement), however, eight weeks of SCiP™ therapy with ABNT resulted in statistically and clinically relevant improvement in GMFM88 scores (mean 23% increase from baseline). We also observed reduced scores on the modified Ashworth scale only with SCiP™ therapy (−11% vs. +5.53% with sham). Similar improvements were observed in sham group but only after the cross over to SCiP™ therapy group at the end of the first eight weeks. Finally, sixteen weeks of SCiP™ therapy with ABNT resulted in further improvement of GMFM88 score. The improvement in GMFM88 scores were maintained at week 26 (10 weeks after the end of therapy), suggesting a sustained effect of SCiP™ therapy.

【 授权许可】

Unknown   
© 2023 Sachdeva, Girshin, Shirkhani, Gad and Edgerton.